Europe Antibiotics Market 2020-2030

Bonafide Trust 26-08-2020 123 Pages Figures : 59 Tables : 87
Region : Europe Category : Lifescience Pharmaceutical

Request new version

Request for updated version of the report at the same price

Order Now

Report Description
Table of Contents
List of Figure Tables

Europe antibiotics market accounted for $11.65 billion in 2019 and will grow by 3.4% annually over 2020-2030 owing to the rising incidences of bacterial infection, growing awareness and need for new drugs and treatment amid the COVID-19 epidemic. Highlighted with 35 tables and 59 figures, this 123-page report “Europe Antibiotics Market 2020-2030 by Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Route of Administration, Drug Type, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe antibiotics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe antibiotics market in every aspect of the classification from perspectives of Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Route of Administration, Drug Type, and Country. Based on Drug Class, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Cephalosporin • Penicillin • Macrolides • Fluoroquinolones • Quinolones • Monobactam • Aminoglycosides • Carbapenem • Other Drug Classes Based on Action Mechanism, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Cell Wall Synthesis Inhibitors • Mycolic Acid Inhibitors • RNA Synthesis Inhibitors • DNA Synthesis Inhibitors • Protein Synthesis Inhibitors • Other Mechanisms Based on Drug Origin, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Natural Antibiotics • Semi-synthetic Antibiotics • Synthetic Antibiotics Based on Activity Spectrum, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Broad-spectrum Antibiotics • Narrow-spectrum Antibiotics Based on Route of Administration, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Oral Administration • Intravenous Administration • Other Administration Routes Based on Drug Type, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Brand Antibiotics • Generic Antibiotics Geographically, the following national/local markets are fully investigated: • Germany • UK • France • Spain • Italy • Russia • Rest of Europe (further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania) For each country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Drug Class, Drug Origin, and Route of Administration over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Specifically, potential risks associated with investing in Europe antibiotics market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players (this may not be a complete list and extra companies can be added upon request): Abbott Laboratories Astellas Pharma AstraZeneca Plc Bayer AG Bristol Myers Squibb Company Cipla Inc. Dr. Reddy’s Laboratories Ltd. Eli Lilly and Company F. Hoffmann-La Roche Ltd. Gilead Sciences, Inc. GlaxoSmithKline plc. Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals) Mayne Pharma Group Ltd. MELINTA THERAPEUTICS, INC. Merck KGaA Novartis AG Pfizer Inc. Sanofi Sun Pharmaceutical Industries Ltd. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

1 Introduction 7

1.1 Industry Definition and Research Scope 7

1.1.1 Industry Definition 7

1.1.2 Research Scope 8

1.2 Research Methodology 11

1.2.1 Overview of Market Research Methodology 11

1.2.2 Market Assumption 12

1.2.3 Secondary Data 12

1.2.4 Primary Data 12

1.2.5 Data Filtration and Model Design 14

1.2.6 Market Size/Share Estimation 15

1.2.7 Research Limitations 16

1.3 Executive Summary 17

2 Market Overview and Dynamics 20

2.1 Market Size and Forecast 20

2.1.1 Impact of COVID-19 on the Market 21

2.2 Major Growth Drivers 23

2.3 Market Restraints and Challenges 27

2.4 Emerging Opportunities and Market Trends 30

2.5 Porter’s Fiver Forces Analysis 34

3 Segmentation of Europe Market by Drug Class 38

3.1 Market Overview by Drug Class 38

3.2 Cephalosporin 40

3.3 Penicillin 41

3.4 Macrolides 42

3.5 Fluoroquinolones 43

3.6 Quinolones 44

3.7 Monobactam 45

3.8 Aminoglycosides 46

3.9 Carbapenem 47

3.10 Other Drug Classes 48

4 Segmentation of Europe Market by Action Mechanism 49

4.1 Market Overview by Action Mechanism 49

4.2 Cell Wall Synthesis Inhibitors 51

4.3 Mycolic Acid Inhibitors 52

4.4 RNA Synthesis Inhibitors 53

4.5 DNA Synthesis Inhibitors 54

4.6 Protein Synthesis Inhibitors 55

4.7 Other Mechanisms 56

5 Segmentation of Europe Market by Drug Origin 57

5.1 Market Overview by Drug Origin 57

5.2 Natural Antibiotics 59

5.3 Semi-synthetic Antibiotics 60

5.4 Synthetic Antibiotics 61

6 Segmentation of Europe Market by Activity Spectrum 62

6.1 Market Overview by Activity Spectrum 62

6.2 Broad-spectrum Antibiotics 64

6.3 Narrow-spectrum Antibiotics 65

7 Segmentation of Europe Market by Route of Administration 66

7.1 Market Overview by Route of Administration 66

7.2 Oral Administration 68

7.3 Intravenous Administration 69

7.4 Other Administration Routes 70

8 Segmentation of Europe Market by Drug Type 71

8.1 Market Overview by Drug Type 71

8.2 Brand Antibiotics 73

8.3 Generic Antibiotics 74

9 European Market 2019-2030 by Country 75

9.1 Overview of European Market 75

9.2 Germany 78

9.3 UK 80

9.4 France 83

9.5 Spain 85

9.6 Italy 87

9.7 Russia 89

9.8 Rest of European Market 91

10 Competitive Landscape 93

10.1 Overview of Key Vendors 93

10.2 New Product Launch, Partnership, Investment, and M&A 96

10.3 Company Profiles 97

Abbott Laboratories 97

Astellas Pharma 99

AstraZeneca Plc 100

Bayer AG 101

Bristol Myers Squibb Company 102

Cipla Inc. 103

Dr. Reddy’s Laboratories Ltd. 104

Eli Lilly and Company 105

F. Hoffmann-La Roche Ltd. 106

Gilead Sciences, Inc. 107

GlaxoSmithKline plc. 108

Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals) 109

Mayne Pharma Group Ltd. 110

MELINTA THERAPEUTICS, INC. 111

Merck KGaA 112

Novartis AG 113

Pfizer Inc. 114

Sanofi 115

Sun Pharmaceutical Industries Ltd. 116

11 Investing in Europe Market: Risk Assessment and Management 117

11.1 Risk Evaluation of Europe Market 117

11.2 Critical Success Factors (CSFs) 120

Related Reports and Products 123

Figure 1. Research Method Flow Chart 11
Figure 2. Breakdown of Primary Research 13
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 15
Figure 4. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 17
Figure 5. Europe Antibiotics Market, 2019-2030, $ mn 20
Figure 6. Impact of COVID-19 on Business 21
Figure 7. Primary Drivers and Impact Factors of Europe Antibiotics Market 23
Figure 8. GDP per capita in the World, 1960-2018, $ thousand 26
Figure 9. Forecast of Middle-class Population by Region, 2015-2030, million 26
Figure 10. Primary Restraints and Impact Factors of Europe Antibiotics Market 27
Figure 11. Investment Opportunity Analysis 31
Figure 12. Porter’s Fiver Forces Analysis of Europe Antibiotics Market 34
Figure 13. Breakdown of Europe Antibiotics Market by Drug Class, 2019-2030, % of Revenue 39
Figure 14. Europe Addressable Market Cap in 2020-2030 by Drug Class, Value ($ mn) and Share (%) 39
Figure 15. Europe Antibiotics Market: Cephalosporin, 2019-2030, $ mn 40
Figure 16. Europe Antibiotics Market: Penicillin, 2019-2030, $ mn 41
Figure 17. Europe Antibiotics Market: Macrolides, 2019-2030, $ mn 42
Figure 18. Europe Antibiotics Market: Fluoroquinolones, 2019-2030, $ mn 43
Figure 19. Europe Antibiotics Market: Quinolones, 2019-2030, $ mn 44
Figure 20. Europe Antibiotics Market: Monobactam, 2019-2030, $ mn 45
Figure 21. Europe Antibiotics Market: Aminoglycosides, 2019-2030, $ mn 46
Figure 22. Europe Antibiotics Market: Carbapenem, 2019-2030, $ mn 47
Figure 23. Europe Antibiotics Market: Other Drug Classes, 2019-2030, $ mn 48
Figure 24. Breakdown of Europe Antibiotics Market by Action Mechanism, 2019-2030, % of Sales Revenue 50
Figure 25. Europe Addressable Market Cap in 2020-2030 by Action Mechanism, Value ($ mn) and Share (%) 50
Figure 26. Europe Antibiotics Market: Cell Wall Synthesis Inhibitors, 2019-2030, $ mn 51
Figure 27. Europe Antibiotics Market: Mycolic Acid Inhibitors, 2019-2030, $ mn 52
Figure 28. Europe Antibiotics Market: RNA Synthesis Inhibitors, 2019-2030, $ mn 53
Figure 29. Europe Antibiotics Market: DNA Synthesis Inhibitors, 2019-2030, $ mn 54
Figure 30. Europe Antibiotics Market: Protein Synthesis Inhibitors, 2019-2030, $ mn 55
Figure 31. Europe Antibiotics Market: Other Mechanisms, 2019-2030, $ mn 56
Figure 32. Breakdown of Europe Antibiotics Market by Drug Origin, 2019-2030, % of Sales Revenue 58
Figure 33. Europe Addressable Market Cap in 2020-2030 by Drug Origin, Value ($ mn) and Share (%) 58
Figure 34. Europe Antibiotics Market: Natural Antibiotics, 2019-2030, $ mn 59
Figure 35. Europe Antibiotics Market: Semi-synthetic Antibiotics, 2019-2030, $ mn 60
Figure 36. Europe Antibiotics Market: Synthetic Antibiotics, 2019-2030, $ mn 61
Figure 37. Breakdown of Europe Antibiotics Market by Activity Spectrum, 2019-2030, % of Revenue 63
Figure 38. Europe Addressable Market Cap in 2020-2030 by Activity Spectrum, Value ($ mn) and Share (%) 63
Figure 39. Europe Antibiotics Market: Broad-spectrum Antibiotics, 2019-2030, $ mn 64
Figure 40. Europe Antibiotics Market: Narrow-spectrum Antibiotics, 2019-2030, $ mn 65
Figure 41. Breakdown of Europe Antibiotics Market by Route of Administration, 2019-2030, % of Revenue 67
Figure 42. Europe Addressable Market Cap in 2020-2030 by Route of Administration, Value ($ mn) and Share (%) 67
Figure 43. Europe Antibiotics Market: Oral Administration, 2019-2030, $ mn 68
Figure 44. Europe Antibiotics Market: Intravenous Administration, 2019-2030, $ mn 69
Figure 45. Europe Antibiotics Market: Other Administration Routes, 2019-2030, $ mn 70
Figure 46. Breakdown of Europe Antibiotics Market by Drug Type, 2019-2030, % of Revenue 71
Figure 47. Europe Addressable Market Cap in 2020-2030 by Drug Type, Value ($ bn) and Share (%) 72
Figure 48. Europe Antibiotics Market: Brand Antibiotics, 2019-2030, $ bn 73
Figure 49. Europe Antibiotics Market: Generic Antibiotics, 2019-2030, $ bn 74
Figure 50. Breakdown of European Antibiotics Market by Country, 2019 and 2030, % of Revenue 76
Figure 51. Contribution to Europe 2020-2030 Cumulative Revenue by Country, Value ($ bn) and Share (%) 77
Figure 52. Antibiotics Market in Germany, 2019-2030, $ bn 78
Figure 53. Antibiotics Market in UK, 2019-2030, $ bn 80
Figure 54. Antibiotics Market in France, 2019-2030, $ bn 83
Figure 55. Antibiotics Market in Spain, 2019-2030, $ bn 85
Figure 56. Antibiotics Market in Italy, 2019-2030, $ bn 87
Figure 57. Antibiotics Market in Russia, 2019-2030, $ bn 89
Figure 58. Antibiotics Market in Rest of Europe, 2019-2030, $ bn 91
Figure 59. Growth Stage of Europe Antibiotics Industry over the Forecast Period 93

Table 1. Snapshot of Global Oncology Informatics Market, 2019-2030 19
Table 2. Main Product Trends and Market Opportunities in Global Oncology Informatics Market 30
Table 3. Global Oncology Informatics Market by Product Type, 2019-2030, $ mn 38
Table 4. Key Products and EHR Vendors 41
Table 5. Key Products and PHM Vendors 43
Table 6. Key Products and CDSS Vendors 45
Table 7. Key Products and DDDI Vendors 47
Table 8. Global Oncology Informatics Market by Cancer Type, 2019-2030, $ mn 51
Table 9. Global Oncology Informatics Market by Application, 2019-2030, $ mn 57
Table 10. Global Oncology Informatics Market by End User, 2019-2030, $ mn 63
Table 11. Global Oncology Informatics Market by Region, 2019-2030, $ mn 71
Table 12. Leading National Oncology Informatics Market, 2019 and 2030, $ mn 73
Table 13. North America Oncology Informatics Market by Country, 2019-2030, $ mn 76
Table 14. U.S. Oncology Informatics Market by Product Type, 2019-2030, $ mn 80
Table 15. U.S. Oncology Informatics Market by Cancer Type, 2019-2030, $ mn 80
Table 16. U.S. Oncology Informatics Market by End User, 2019-2030, $ mn 80
Table 17. Canada Oncology Informatics Market by Product Type, 2019-2030, $ mn 83
Table 18. Canada Oncology Informatics Market by Cancer Type, 2019-2030, $ mn 83
Table 19. Canada Oncology Informatics Market by End User, 2019-2030, $ mn 83
Table 20. Mexico Oncology Informatics Market by Product Type, 2019-2030, $ mn 85
Table 21. Mexico Oncology Informatics Market by Cancer Type, 2019-2030, $ mn 85
Table 22. Mexico Oncology Informatics Market by End User, 2019-2030, $ mn 85
Table 23. Europe Oncology Informatics Market by Country, 2019-2030, $ mn 89
Table 24. Germany Oncology Informatics Market by Product Type, 2019-2030, $ mn 91
Table 25. Germany Oncology Informatics Market by Cancer Type, 2019-2030, $ mn 91
Table 26. Germany Oncology Informatics Market by End User, 2019-2030, $ mn 91
Table 27. UK Oncology Informatics Market by Product Type, 2019-2030, $ mn 93
Table 28. UK Oncology Informatics Market by Cancer Type, 2019-2030, $ mn 93
Table 29. UK Oncology Informatics Market by End User, 2019-2030, $ mn 93
Table 30. France Oncology Informatics Market by Product Type, 2019-2030, $ mn 95
Table 31. France Oncology Informatics Market by Cancer Type, 2019-2030, $ mn 95
Table 32. France Oncology Informatics Market by End User, 2019-2030, $ mn 95
Table 33. Spain Oncology Informatics Market by Product Type, 2019-2030, $ mn 97
Table 34. Spain Oncology Informatics Market by Cancer Type, 2019-2030, $ mn 97
Table 35. Spain Oncology Informatics Market by End User, 2019-2030, $ mn 97
Table 36. Italy Oncology Informatics Market by Product Type, 2019-2030, $ mn 99
Table 37. Italy Oncology Informatics Market by Cancer Type, 2019-2030, $ mn 99
Table 38. Italy Oncology Informatics Market by End User, 2019-2030, $ mn 99
Table 39. Russia Oncology Informatics Market by Product Type, 2019-2030, $ mn 101
Table 40. Russia Oncology Informatics Market by Cancer Type, 2019-2030, $ mn 101
Table 41. Russia Oncology Informatics Market by End User, 2019-2030, $ mn 101
Table 42. Oncology Informatics Market in Rest of Europe by Country, 2019-2030, $ mn 103
Table 43. APAC Oncology Informatics Market by Country, 2019-2030, $ mn 106
Table 44. Japan Oncology Informatics Market by Product Type, 2019-2030, $ mn 110
Table 45. Japan Oncology Informatics Market by Cancer Type, 2019-2030, $ mn 110
Table 46. Japan Oncology Informatics Market by End User, 2019-2030, $ mn 110
Table 47. China Oncology Informatics Market by Product Type, 2019-2030, $ mn 112
Table 48. China Oncology Informatics Market by Cancer Type, 2019-2030, $ mn 112
Table 49. China Oncology Informatics Market by End User, 2019-2030, $ mn 112
Table 50. Australia Oncology Informatics Market by Product Type, 2019-2030, $ mn 114
Table 51. Australia Oncology Informatics Market by Cancer Type, 2019-2030, $ mn 114
Table 52. Australia Oncology Informatics Market by End User, 2019-2030, $ mn 114
Table 53. India Oncology Informatics Market by Product Type, 2019-2030, $ mn 116
Table 54. India Oncology Informatics Market by Cancer Type, 2019-2030, $ mn 116
Table 55. India Oncology Informatics Market by End User, 2019-2030, $ mn 116
Table 56. South Korea Oncology Informatics Market by Product Type, 2019-2030, $ mn 118
Table 57. South Korea Oncology Informatics Market by Cancer Type, 2019-2030, $ mn 118
Table 58. South Korea Oncology Informatics Market by End User, 2019-2030, $ mn 118
Table 59. Oncology Informatics Market in Rest of APAC by Country, 2019-2030, $ mn 120
Table 60. South America Oncology Informatics Market by Country, 2019-2030, $ mn 123
Table 61. Argentina Oncology Informatics Market by Product Type, 2019-2030, $ mn 125
Table 62. Argentina Oncology Informatics Market by Cancer Type, 2019-2030, $ mn 125
Table 63. Argentina Oncology Informatics Market by End User, 2019-2030, $ mn 125
Table 64. Brazil Oncology Informatics Market by Product Type, 2019-2030, $ mn 127
Table 65. Brazil Oncology Informatics Market by Cancer Type, 2019-2030, $ mn 127
Table 66. Brazil Oncology Informatics Market by End User, 2019-2030, $ mn 127
Table 67. Chile Oncology Informatics Market by Product Type, 2019-2030, $ mn 129
Table 68. Chile Oncology Informatics Market by Cancer Type, 2019-2030, $ mn 129
Table 69. Chile Oncology Informatics Market by End User, 2019-2030, $ mn 129
Table 70. MEA Oncology Informatics Market by Country, 2019-2030, $ mn 133
Table 71. UAE Oncology Informatics Market by Product Type, 2019-2030, $ mn 135
Table 72. UAE Oncology Informatics Market by Cancer Type, 2019-2030, $ mn 135
Table 73. UAE Oncology Informatics Market by End User, 2019-2030, $ mn 135
Table 74. Saudi Arabia Oncology Informatics Market by Product Type, 2019-2030, $ mn 137
Table 75. Saudi Arabia Oncology Informatics Market by Cancer Type, 2019-2030, $ mn 137
Table 76. Saudi Arabia Oncology Informatics Market by End User, 2019-2030, $ mn 137
Table 77. South Africa Oncology Informatics Market by Product Type, 2019-2030, $ mn 139
Table 78. South Africa Oncology Informatics Market by Cancer Type, 2019-2030, $ mn 139
Table 79. South Africa Oncology Informatics Market by End User, 2019-2030, $ mn 139
Table 80. Breakdown of Global Market by Key Vendor, 2019, % 143
Table 81. Cerner Corporation: Company Snapshot 146
Table 82. Cerner Corporation: Business Segmentation 146
Table 83. Cerner Corporation: Product Portfolio 147
Table 84. Cerner Corporation: Revenue, 2016-2018, $ mn 147
Table 85. Cerner Corporation: Recent Developments 147
Table 86. Risk Evaluation for Investing in Global Market, 2019-2030 165
Table 87. Critical Success Factors and Key Takeaways 168

Interested in this report?
Get your FREE sample!

Safe and Secure SSl Encryption

Licensing options

3000
USD

Single User License
Site License
Global User License

How client has rates us?

Requirement Gathering & Methodology

Data Collection Techniques

Our Research Team & Data Sourcing

Data Science & Analytical Tools

Data Visualization & Presentation Skills

Project/ Report Delivery & After Sales Services

Testimonial

READY TO MIX MARKET HAS HELPED US TO UNDERSTAND PRODUCT, PRICE & VARIENTS OF ALL THE COMPETITION INCLUDING SMALL STARTUPS/REGIONAL PLAYERS.

PRODUCT DEVELOPMENT MANAGER

CEO

Vivek Arora

BEING A STARTUP WE WERE NOT AWARE ABOUT E-COMMERCE LOGISTICS, THE REPORT HAS RESOLVED ALL OUR QUERIES. THE TEAM HAVE IN DEPTH KNOWLEDGE OF LOGISTICS. REMARKABLE!!

EXECUTIVE DIRECTOR

Rahul Roy

THE REPORT WAS GOOD FOR OUR STUDY, I WOULD STRONGLY RECOMMEND BONAFIDE RESEARCH. A VERY CUSTOMER CENTRIC AND APPROACHABLE TEAM.

SALES DIRECTOR

Arjun Prasad

THE COMPANY WHICH THOROUGHLY UNDERSTANDS INDIAN CONSUMER AND INDIAN MARKET. WE ARE REALLY HAPPY TO WORK WITH BONAFIDE RESEARCH

MARKETING MANAGER

President

Manish Verma

Bonafide Research did an outstanding work on Global Hand Sanitizer project. It was indeed a comprehensive report that gave us revenue impacting solution enabling us to plan the right move.

MARKETING DIRECTOR

Gautam Saxena

The study done by Bonafide Research was customized with all our needs. We were extremely impressed by the simple but comprehensive presentation of the study and the quality of work done.

PRODUCT MANAGER

Tom Stone

I’m glad I decided to work with you. Thankful to the team for the amazing coordination, it was indeed a good experience, would definitely recommend and come back for future prospects.

Associate Director

Mark Wood

Europe Antibiotics Market 2020-2030

Europe Antibiotics Market 2020-2030